Prof François Duhoux on TROPION-Breast 01

During the general session 2 at the SABCS 2023, Prof Adity Bardia, medical oncologist and Director of the Breast Cancer Research Program at the Massachusetts General Hospital in Boston, presented the results from the TROPION-Breast 01 study. Prof François Duhoux, medical oncologist and head of clinic of the department of oncology at the Cliniques Universitaires in Brussels, commented on this study.

TROPION-Breast01, a pivotal phase 3 randomised study, assessed patients with ER+/HER2- metastatic breast cancer ineligible for further endocrine therapy after one or two lines of chemotherapy. The study compared datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate targeting TROP2, with physician’s choice chemotherapy options (eribulin, vinorelbine, gemcitabine, or capecitabine).

The primary endpoint PFS was met, revealing a significant advantage for Dato-DXd. Patients treated with Dato-DXd exhibited a median PFS of 6.9 months, compared to 4.5 months with chemotherapy of physician’s choice (hazard ratio: 0.64). This translated into an extended duration before initiating subsequent lines of therapy, and the favourable outcomes were consistent across all patient subgroups.

Noteworthy was the comparable efficacy of Dato-DXd in patients with brain metastases, a crucial consideration in later lines of therapy. Although stomatitis emerged as a prominent side effect, aligning with existing literature, the study indicated that the quality of life was preserved and even numerically higher in the Dato-DXd group.

In summary, TROPION-Breast01 demonstrated the efficacy of Dato-DXd over chemotherapy in ER+/HER2- metastatic breast cancer patients ineligible for further endocrine therapy after one or two lines of chemotherapy. The findings underscore the potential of TROP2-targeted therapy as a valuable treatment option in this challenging clinical scenario.  

Reference:

Bardia A.. et al., Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Results from TROPION-Breast01.  SABCS 2023 # GS02-01